INFO SHEET

Patient-Derived Liver Organoids for MASLD Research

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disease worldwide, affecting approximately 25% of the global population. MASLD spans a spectrum from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), which can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. Despite major investment, progress has been slowed by a familiar bottleneck: the lack of physiologically relevant, scalable primary human models that enable detailed study of disease onset and early progression—the stage where intervention could have the greatest impact.

Patient-Derived Liver Organoids: A Physiologically Relevant Model for Early MASLD

HUB Organoids' patient-derived organoids (PDOs) provide a highly relevant preclinical platform to study early-stage MASLD biology in a patient-specific context. Unlike traditional cell lines and engineered systems, HUB PDOs are derived from primary human tissue, never passaged in animals, and genetically stable—preserving the genomic, transcriptomic, and phenotypic features of the original tissue.

Using a newly developed assay in normal human liver organoids, we recapitulate early-stage MASLD and its metabolic context in vitro, including key hallmarks such as steatosis and lipotoxicity.

Download Our Brochure to Learn About:

• How HUB Organoids models early-stage MASLD and its progression in a primary human context
• Our multi-parametric, imaging-based readout platform for quantitative assessment of lipid accumulation, cell viability, reactive oxygen species, and mitochondrial membrane potential
• How the platform supports disease biology studies, compound screening, interception studies, and patient-specific response profiling
• What you receive: study design support, quantitative data packages, and optional complementary biomarkers suited for go/no-go decisions

FOR RESEARCH USE ONLY. Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany